| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| R G Pertwe. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17828291. |
delta9-thc, the main psychotropic constituent of cannabis, is a cb1 and cb2 receptor partial agonist and in line with classical pharmacology, the responses it elicits appear to be strongly influenced both by the expression level and signalling efficiency of cannabinoid receptors and by ongoing endogenous cannabinoid release. |
2008-04-02 |
2023-08-12 |
Not clear |
| K L Wright, M Duncan, K A Sharke. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17906675. |
traditional and anecdotal use of marijuana for gastrointestinal disorders, such as diarrhoea and abdominal cramps is recognized, but the therapeutic benefit of cannabinoids in the 21st century is overshadowed by the psychoactive problems associated with cb1 receptor activation. |
2008-04-02 |
2023-08-12 |
Not clear |
| B N Ditte. Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17922025. |
the best-studied plant cannabinoid, delta9-tetrahydrocannabinol (thc), produced by cannabis sativa and found in marijuana, has shown evidence of being immunosuppressive in both in vivo and in vitro. |
2008-04-02 |
2023-08-12 |
mouse |
| Estera Páldyová, E Bereczki, M Sántha, T Wenger, Anna Borsodi, S Benyh. Altered gene expression and functional activity of opioid receptors in the cerebellum of CB1 cannabinoid receptor knockout mice after acute treatments with cannabinoids. Acta biologica Hungarica. vol 58 Suppl. 2008-04-02. PMID:18297798. |
the goal of this study was to evaluate whether acute treatments by endogenous cannabinoid agonist, selective cb1 or cb2 receptor antagonists modulate the expression of mu- (mor) and delta- (dor) opioid receptor mrna levels and functional activity in the cerebellum of transgenic mice deficient in the cb1 type of cannabis receptors. |
2008-04-02 |
2023-08-12 |
mouse |
| Patrick D Skosnik, Sohee Park, Laura Dobbs, Wendi L Gardne. Affect processing and positive syndrome schizotypy in cannabis users. Psychiatry research. vol 157. issue 1-3. 2008-03-25. PMID:17897720. |
while cannabis is associated with positive syndrome schizophrenia (sz), it is unclear whether cannabinoids are also related to negative symptoms such as affective blunting. |
2008-03-25 |
2023-08-12 |
Not clear |
| Roger Cachope, Ken Mackie, Antoine Triller, John O'Brien, Alberto E Pered. Potentiation of electrical and chemical synaptic transmission mediated by endocannabinoids. Neuron. vol 56. issue 6. 2008-03-21. PMID:18093525. |
similar interactions between endocannabinoid and dopaminergic systems may be widespread and potentially relevant for the motor and rewarding effects of cannabis derivatives. |
2008-03-21 |
2023-08-12 |
Not clear |
| Marilyn A Huestis, Susan J Boyd, Stephen J Heishman, Kenzie L Preston, Denis Bonnet, Gerard Le Fur, David A Gorelic. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology. vol 194. issue 4. 2008-03-17. PMID:17619859. |
a single 90-mg dose of the cannabinoid cb1 receptor antagonist rimonabant attenuates effects of smoked cannabis in humans. |
2008-03-17 |
2023-08-12 |
Not clear |
| Frederike K Engels, Floris A de Jong, Ron H J Mathijssen, Joëlle A Erkens, Ron M Herings, Jaap Verwei. Medicinal cannabis in oncology. European journal of cancer (Oxford, England : 1990). vol 43. issue 18. 2008-03-10. PMID:17976975. |
in the netherlands, since september 2003, a legal medicinal cannabis product, constituting the whole range of cannabinoids, is available for clinical research, drug development strategies, and on prescription for patients. |
2008-03-10 |
2023-08-12 |
Not clear |
| Karin Woelkart, Outi M H Salo-Ahen, Rudolf Baue. CB receptor ligands from plants. Current topics in medicinal chemistry. vol 8. issue 3. 2008-03-07. PMID:18289087. |
cannabis sativa l. with the known plant cannabinoid, delta(9-)tetrahydrocannabinol (thc) and echinacea species with the cannabinoid (cb) receptor-binding lipophilic alkamides are the best known herbal cannabimimetics. |
2008-03-07 |
2023-08-12 |
Not clear |
| Georg Juckel, Patrik Roser, Thomas Nadulski, Andreas M Stadelmann, Jürgen Gallina. Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophrenia research. vol 97. issue 1-3. 2008-03-04. PMID:17884351. |
currently, there are discussions focusing on the close relationship between cannabis, the endocannabinoid and dopaminergic system, and the onset of schizophrenic psychosis. |
2008-03-04 |
2023-08-12 |
human |
| C R Hiley, S S Kau. GPR55 and the vascular receptors for cannabinoids. British journal of pharmacology. vol 152. issue 5. 2008-02-25. PMID:17704825. |
cb1 and cb2 receptors mediate most responses to cannabinoids but not some of the cardiovascular actions of endocannabinoids such as anandamide and virodhamine, or those of some synthetic agents, like abnormal cannabidiol (abn-cbd). |
2008-02-25 |
2023-08-12 |
mouse |
| I S McGregor, J C Arnol. Cannabis reward: biased towards the fairer sex? British journal of pharmacology. vol 152. issue 5. 2008-02-25. PMID:17891161. |
recent breakthrough discoveries of intravenous thc self-administration in rhesus monkeys and self-administration of the synthetic cannabinoid agonist win 55,212-2 in rats have allowed new studies of the genetic, neural and environmental determinants of cannabis use. |
2008-02-25 |
2023-08-12 |
rat |
| A Preet, R K Ganju, J E Groopma. Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene. vol 27. issue 3. 2008-02-15. PMID:17621270. |
delta(9)-tetrahydrocannabinol (thc) is the primary cannabinoid of marijuana and has been shown to either potentiate or inhibit tumor growth, depending on the type of cancer and its pathogenesis. |
2008-02-15 |
2023-08-12 |
mouse |
| Sean D McAllister, Rigel T Christian, Maxx P Horowitz, Amaia Garcia, Pierre-Yves Despre. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular cancer therapeutics. vol 6. issue 11. 2008-02-15. PMID:18025276. |
here, we report that cannabidiol (cbd), a cannabinoid with a low-toxicity profile, could down-regulate id-1 expression in aggressive human breast cancer cells. |
2008-02-15 |
2023-08-12 |
mouse |
| P Massi, M Valenti, A Vaccani, V Gasperi, G Perletti, E Marras, F Fezza, M Maccarrone, D Parolar. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. Journal of neurochemistry. vol 104. issue 4. 2008-02-14. PMID:18028339. |
5-lipoxygenase and anandamide hydrolase (faah) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. |
2008-02-14 |
2023-08-12 |
mouse |
| P Massi, M Valenti, A Vaccani, V Gasperi, G Perletti, E Marras, F Fezza, M Maccarrone, D Parolar. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. Journal of neurochemistry. vol 104. issue 4. 2008-02-14. PMID:18028339. |
it has been recently reported that cannabidiol (cbd), a non-psychoactive cannabinoid, is able to kill glioma cells, both in vivo and in vitro, independently of cannabinoid receptor stimulation. |
2008-02-14 |
2023-08-12 |
mouse |
| R G Pertwe. GPR55: a new member of the cannabinoid receptor clan? British journal of pharmacology. vol 152. issue 7. 2008-02-05. PMID:17876300. |
gpr55 was activated by a range of plant, synthetic and endogenous cannabinoids and blocked by the non-psychoactive phytocannabinoid, cannabidiol. |
2008-02-05 |
2023-08-12 |
mouse |
| Raul Gonzale. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychology review. vol 17. issue 3. 2008-01-17. PMID:17680367. |
this has been fueled, in part, by characterization of an endocannabinoid signaling system in the brain through which cannabis exerts its psychoactive effects. |
2008-01-17 |
2023-08-12 |
human |
| David R Janero, Alexandros Makriyanni. Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity. Current psychiatry reports. vol 9. issue 5. 2008-01-10. PMID:17915075. |
the endogenous endocannabinoid system encompasses a family of natural signaling lipids ("endocannabinoids") functionally related to (9)-tetrahydrocannabinol, the psychoactive ingredient of marijuana (cannabis), along with proteins that modulate the endocannabinoids, including enzymes, transporters, and receptors. |
2008-01-10 |
2023-08-12 |
Not clear |
| Gustavo González-Cuevas, Harinder Aujla, Rémi Martin-Fardon, José Antonio López-Moreno, Miguel Navarro, Friedbert Weis. Subchronic cannabinoid agonist (WIN 55,212-2) treatment during cocaine abstinence alters subsequent cocaine seeking behavior. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 11. 2008-01-09. PMID:17392740. |
the co-abuse of marijuana with cocaine is widespread, but it has not been until recently that the relationship between the behavioral effects of cannabinoids and cocaine has begun to be unveiled in animal models. |
2008-01-09 |
2023-08-12 |
human |